- Home
- About Us
- Service
- Application
- Technology
- Resource
- Contact Us
News and Events
HaploX Collaborates with The First Hospital of China Medical University, Groundbreaking ctDNA-MRD Study Selected as Oral Presentation for 2026 EAU Congress
2026-03-18
HaploX and The First Hospital of China Medical University’s ctDNA-MRD Study Selected as Oral Presentation for 2026 EAU Congress
In March 2026, the 41st Annual Congress of the European Association of Urology (EAU) was held in London. The joint study on ctDNA-MRD monitoring for genitourinary cancers by HaploX and The First Hospital of China Medical University was successfully selected for the congress's Oral Presentation, with its achievements attracting international academic attention.
Supported by HaploX's core ultra-trace liquid biopsy technology, the study customized personalized MRD detection panels for 61 genitourinary cancer patients and conducted postoperative dynamic monitoring combined with 100,000× ultra-deep targeted sequencing, achieving several key clinical outcomes: it can detect molecular recurrence 7 to 466 days earlier than imaging, confirming that MRD status is an important molecular marker for postoperative prognosis of genitourinary cancers. It can also effectively identify suspected recurrence and reflect treatment response, providing a scientific basis for clinical precision diagnosis and treatment.
HaploX provided comprehensive technical support for the entire research process, including whole-exome sequencing of tumor tissue DNA, the design of patient-tailored tumor-informed MRD panels (up to 40 loci), and longitudinal ctDNA-MRD surveillance using 100,000× ultra-deep targeted sequencing—a core technology of HaploX that excels in capturing ultra-low-frequency ctDNA mutations with high accuracy.This study fully verified the technical strength and clinical value of the product, and highlighted HaploX's core contribution in the R&D and clinical translation of ctDNA-MRD technology. It provides high-quality evidence-based evidence for the personalized postoperative management of genitourinary cancers and boosts the international development of precision cancer medicine.
